The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.

“This approach will help researchers develop more ‘synthetic lethal’ treatments, like PARP inhibitors. Drugs like these will treat breast cancer and other cancers in a way that largely leaves a ...

The common side effects of all PARP inhibitors include: nausea, vomiting, fatigue, upset stomach and bone marrow issues. Each of three types of PARP inhibitors–Niraparib, Rucaparib, and Olaparib–have ...

This Research Topic is part of a series with:Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and MoreOvarian cancer is the malignancy with the highest rate ...

Breast cancer is the most prevalent malignancy among women worldwide. Despite significant advances in treatment, it remains one of the leading causes of female mortality. The inability to effectively ...

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

The Institute for Drug Research, The School of Pharmacy, The Faculty of Medicine, The Hebrew University, POB 12271, Jerusalem 9112001, Israel ...